AstraZeneca said Wednesday that a main analysis of its Phase 3 trial data verified its coronavirus vaccine’s “safety” with a 76?ficacy rate against symptomatic COVID.
Flashback: The company reported on Monday that a U.S. trial discovered its vaccine 79?fective, however dealt with reaction after NIAID said Tuesday it may have consisted of info that provided an “ insufficient view of the effectiveness data” in its U.S. results.
The big photo: AstraZeneca currently faced debate after more than a dozen nations suspended use of its vaccine in mid-March due to reports of blood clots in some people who had gotten the shot.
http://businessadministrationcertification.com/astrazeneca-concerns-new-phase-3-information-for-covid-vaccine-confirming-security-and-efficacy/
No comments:
Post a Comment